(Hypertension. 1995;25:715-719.)
© 1995 American Heart Association, Inc.
Articles |
Muscle Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive Rats
From the Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston.
Correspondence to Lee Chao, PhD, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC 29425.
Abstract We recently found that transgenic mice expressing human tissue kallikrein develop sustained hypotension. The result suggests that a continuous supply of human tissue kallikrein could have a prolonged effect on blood pressure reduction. In the present study, we investigated the potential of using human tissue kallikrein for gene therapy by injecting a kallikrein gene construct into the skeletal muscle of spontaneously hypertensive rats. Expression of the human tissue kallikrein messenger RNA in spontaneously hypertensive rats was identified by reverse transcription–polymerase chain reaction with Southern blot. Human tissue kallikrein was detected in the injected animals by an enzyme-linked immunosorbent assay. Injection of the human kallikrein gene into spontaneously hypertensive rats caused a significant reduction of systemic blood pressure, ranging from 15 to 26 mm Hg, compared with the control group. The differences were significant 1 week after the injection and continued for more than 2 months. Blood pressure reduction could be reversed after the administration of the bradykinin antagonist Hoe 140. The results indicate that somatic delivery of the human tissue kallikrein gene induces a sustained reduction of systemic blood pressure in spontaneously hypertensive rats. The present study raises the possibility of applying kallikrein gene therapy to the treatment of human hypertensive diseases.
Key Words: kallikrein • rats, inbred SHR • gene therapy • blood pressure
This article has been cited by other articles:
 |
|
 |
|
  G. J Dietze and E. J Henriksen Review: Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 75 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Yuan, J. Deng, T. Wang, C. Zhao, X. Xu, P. Wang, J. W. Voltz, M. L. Edin, X. Xiao, L. Chao, et al. Tissue Kallikrein Reverses Insulin Resistance and Attenuates Nephropathy in Diabetic Rats by Activation of Phosphatidylinositol 3-Kinase/Protein Kinase B and Adenosine 5'-Monophosphate-Activated Protein Kinase Signaling Pathways Endocrinology, May 1, 2007; 148(5): 2016 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chao and L. Chao Kallikrein-kinin in stroke, cardiovascular and renal disease Exp Physiol, May 1, 2005; 90(3): 291 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhao, P. Wang, X. Xiao, J. Chao, L. Chao, D. W. Wang, and D. C. Zeldin Gene Therapy With Human Tissue Kallikrein Reduces Hypertension and Hyperinsulinemia in Fructose-Induced Hypertensive Rats Hypertension, November 1, 2003; 42(5): 1026 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dendorfer, S. Wolfrum, M. Wagemann, F. Qadri, and P. Dominiak Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2182 - H2188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yoshida, J. J Zhang, L. Chao, and J. Chao Kallikrein Gene Delivery Attenuates Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion Hypertension, January 1, 2000; 35(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jin, L. Chao, and J. Chao Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR Am J Physiol Renal Physiol, March 1, 1999; 276(3): F476 - F484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yayama, C. Wang, L. Chao, and J. Chao Kallikrein Gene Delivery Attenuates Hypertension and Cardiac Hypertrophy and Enhances Renal Function in Goldblatt Hypertensive Rats Hypertension, May 1, 1998; 31(5): 1104 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yu, D. W. Bowden, B. J. Spray, S. S. Rich, and B. I. Freedman Identification of Human Plasma Kallikrein Gene Polymorphisms and Evaluation of Their Role in End-Stage Renal Disease Hypertension, April 1, 1998; 31(4): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Colman and A. H. Schmaier Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes Blood, November 15, 1997; 90(10): 3819 - 3843. [Full Text] [PDF]
|
|